Google
Trusted Resources: News & Events
Latest announcements and gatherings
First systemic evidence for safety of tPA in stroke patients with sickle cell disease
In the largest report on acute stroke in sickle cell disease to date, researchers at the Medical University of South Carolina and elsewhere provide the first systemic evidence for the safe use of tPA in stroke patients with sickle cell disease.
Adult patients with sickle cell disease (SCD) who experience a stroke caused by a clot (i.e., ischemic strokes or IS) can be treated safely with tissue plasminogen activator (tPA) if they qualify, report investigators at the Medical University of South Carolina (MUSC) and elsewhere in the March 2017 issue of Stroke.
+myBinderRelated Content
-
Gene therapy targets sickle-cell diseaseElliott Vichinsky estimates that at leas...
-
Mortality trends and causes of death in persons with sickle cell disease in the United States, 1979-2014Sickle cell disease (SCD)-related mortal...
-
The severity of anaemia depletes cerebrovascular dilatory reserve in children with sickle cell disease: a quantitati...Overt ischaemic stroke is one of the mos...
-
Capitol Hill Briefing Held to Encourage Sickle Cell Research and TreatmentEarlier today, a briefing was hosted on ...
-
Novartis acquires US pharma research firm Selexys PharmaceuticalsSwiss-based pharmaceuticals giant Novart...
-
NIH Launches new Collaboration to Develop Gene-Based Cures for Sickle Cell Disease and HIV on Global ScaleThe National Institutes of Health plans ...
-
Jennifer Doudna on ethics of gene editinghttps://www.youtube.com/watch?v=8Ijr1ccY...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.